News

Pfizer and Flynn Pharma accused of overcharging by CMA


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Pfizer and Flynn Pharma accused of overcharging by CMA

 

Date: 06/08/2015


Pharmaceutical firms Pfizer and Flynn Pharma have been accused by the UK's competition watchdog of charging "excessive and unfair" prices for an anti-epilepsy drug.

Phenytoin sodium capsules, used by 50,000 people in Britain, are made by Pfizer and sold by Flynn.

Pfizer said it was co-operating with the Competition and Markets Authority.

When Pfizer made the drug under its Epanutin brand name, the NHS spent about £2.3m on the drug, the CMA said.

This amount soared to £50m in 2013.

The CMA said Pfizer sold UK distribution rights to Flynn in 2012, but continued to make and supply the drug to the company.

For more click here

Source: BBC

© Catalyst Innovation Portal 2019